Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Amortizatization of Intangibles: 2020-2024

Historic Amortizatization of Intangibles for Day One Biopharmaceuticals (DAWN) over the last 5 years, with Dec 2024 value amounting to $6.4 million.

  • Day One Biopharmaceuticals' Amortizatization of Intangibles rose 33.33% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 130.18%. This contributed to the annual value of $6.4 million for FY2024, which is 36.60% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Amortizatization of Intangibles of $6.4 million as of FY2024, which was down 36.60% from $10.1 million recorded in FY2023.
  • Day One Biopharmaceuticals' 5-year Amortizatization of Intangibles high stood at $10.1 million for FY2023, and its period low was $139,000 during FY2020.
  • Its 3-year average for Amortizatization of Intangibles is $6.2 million, with a median of $6.4 million in 2024.
  • In the last 5 years, Day One Biopharmaceuticals' Amortizatization of Intangibles skyrocketed by 1,034.08% in 2022 and then tumbled by 36.60% in 2024.
  • Yearly analysis of 5 years shows Day One Biopharmaceuticals' Amortizatization of Intangibles stood at $139,000 in 2020, then increased by 28.78% to $179,000 in 2021, then skyrocketed by 1,034.08% to $2.0 million in 2022, then skyrocketed by 396.45% to $10.1 million in 2023, then slumped by 36.60% to $6.4 million in 2024.